Figure 1.

Mean (SD) plasma concentration‐time profiles of VIB4920 for Study 1 (a) where animals were given five weekly doses of VIB4920 followed by a 20‐week recovery period (for all groups, dosing phase N = 6, recovery phase N = 3), Study 2 (b) where animals were given five weekly doses of VIB4920 followed by a 27‐week recovery period (for vehicle and 300 mg·kg⁻¹ groups, dosing phase N = 12, recovery phase N = 6; for 50 and 150 mg·kg⁻¹ groups, dosing phase N = 6, recovery phase N = 3), and Study 3 where animals were given 28 weekly i.v. (c) or s.c. (d) doses of VIB4920 followed by a 29‐week recovery period (for all groups, dosing phase N = 12, recovery phase N = 6). i.v., intravenous; s.c., subcutaneous